“Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients With Moderate-to-Severe Psoriasis”. 2018. SKIN The Journal of Cutaneous Medicine 2 (S1): S1. https://doi.org/10.25251/skin.2.supp.1.